176 related articles for article (PubMed ID: 2693029)
61. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
[TBL] [Abstract][Full Text] [Related]
62. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
Kawamori R; Bando K; Yamasaki Y; Kubota M; Watarai T; Iwama N; Shichiri M; Kamada T
Diabetes Care; 1989; 12(10):680-5. PubMed ID: 2515048
[TBL] [Abstract][Full Text] [Related]
63. The enteric enhancement of glucose-stimulated insulin release. The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus.
Elahi D; Andersen DK; Muller DC; Tobin JD; Brown JC; Andres R
Diabetes; 1984 Oct; 33(10):950-7. PubMed ID: 6383904
[TBL] [Abstract][Full Text] [Related]
64. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
65. Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly.
Peracchi M; Porretti S; Gebbia C; Pagliari C; Bucciarelli P; Epaminonda P; Manenti S; Arosio M
Eur J Endocrinol; 2001 Jul; 145(1):R1-4. PubMed ID: 11415859
[TBL] [Abstract][Full Text] [Related]
66. The effects of porcine GIP on insulin secretion and glucose clearance in the pig.
Wolffbrandt KH; Damm Jørgensen K; Moody AJ; Pedersen PC
Horm Metab Res; 1986 Mar; 18(3):159-62. PubMed ID: 3516832
[TBL] [Abstract][Full Text] [Related]
67. Effect of glucose-dependent insulinotropic polypeptide (GIP) on insulin response to glucose in acromegalics.
Pierluissi J; de Pierluissi RM
Acta Cient Venez; 1995; 46(2):89-96. PubMed ID: 9279024
[TBL] [Abstract][Full Text] [Related]
68. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT.
Alssema M; Rijkelijkhuizen JM; Holst JJ; Teerlink T; Scheffer PG; Eekhoff EM; Gastaldelli A; Mari A; Hart LM; Nijpels G; Dekker JM
Eur J Endocrinol; 2013 Oct; 169(4):421-30. PubMed ID: 23864340
[TBL] [Abstract][Full Text] [Related]
69. Gastric inhibitory polypeptide in obesity and diabetes mellitus.
Service FJ; Rizza RA; Westland RE; Hall LD; Gerich JE; Go VL
J Clin Endocrinol Metab; 1984 Jun; 58(6):1133-40. PubMed ID: 6373812
[TBL] [Abstract][Full Text] [Related]
70. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8.
Fieseler P; Bridenbaugh S; Nustede R; Martell J; Orskov C; Holst JJ; Nauck MA
Am J Physiol; 1995 May; 268(5 Pt 1):E949-55. PubMed ID: 7762650
[TBL] [Abstract][Full Text] [Related]
71. Increased gastric inhibitory polypeptide is not reduced in patients with noninsulin-dependent diabetes mellitus treated with intense insulin therapy.
Lardinois CK; Mazzaferri EL; Starich GH; Hollenbeck CB; Reaven GM
J Clin Endocrinol Metab; 1985 Dec; 61(6):1089-92. PubMed ID: 3902866
[TBL] [Abstract][Full Text] [Related]
72. Postprandial hormone and metabolic responses in simulated shift work.
Hampton SM; Morgan LM; Lawrence N; Anastasiadou T; Norris F; Deacon S; Ribeiro D; Arendt J
J Endocrinol; 1996 Nov; 151(2):259-67. PubMed ID: 8958786
[TBL] [Abstract][Full Text] [Related]
73. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
74. Influence of ingested load on postprandial insulin secretion. Rôle of gastric inhibitory polypeptide (GIP).
Beck B; Villaume C
Arch Int Physiol Biochim; 1985 Jun; 93(2):101-6. PubMed ID: 2412503
[TBL] [Abstract][Full Text] [Related]
75. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.
Levy JC; Rudenski A; Burnett M; Knight R; Matthews DR; Turner RC
Diabetologia; 1991 Jul; 34(7):488-99. PubMed ID: 1916054
[TBL] [Abstract][Full Text] [Related]
76. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.
Ahrén B; Holst JJ; Mari A
Diabetes Care; 2003 Oct; 26(10):2860-4. PubMed ID: 14514592
[TBL] [Abstract][Full Text] [Related]
77. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance.
Theodorakis MJ; Carlson O; Muller DC; Egan JM
Diabetes Care; 2004 Jul; 27(7):1692-8. PubMed ID: 15220248
[TBL] [Abstract][Full Text] [Related]
78. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
79. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ
Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881
[TBL] [Abstract][Full Text] [Related]
80. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
Wice BM; Reeds DN; Tran HD; Crimmins DL; Patterson BW; Dunai J; Wallendorf MJ; Ladenson JH; Villareal DT; Polonsky KS
Diabetes; 2012 Jul; 61(7):1793-800. PubMed ID: 22522617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
